

Senzime's on-line glucose monitoring instrument enters market introduction stage

Strategic partner Applikon Biotechnology has decided to exhibit Senzime's bioprocess glucose analyzer at HET Instrument (Amsterdam) and Biotechnica (Hannover), both key events for the bioprocess and pharmaceutical industries. The two fairs will take place during September and October, 2010 and attracts visitors from all over Europe and abroad.

"This is another very important step for Senzime. We are working hard to bringing our on-line glucose monitoring instrument to the market and the fact that Applikon Biotechnology, one of the leading suppliers of bioprocess equipment to the pharmaceutical and other industries, now has decided to officially present our product is a great reward. It makes us really proud of what we have achieved and excited about what's to come", says Staffan Boström, CEO of Senzime.

Glucose monitoring in pharmaceutical production processes

The need for continuous monitoring of production processes in drug development and large scale drug manufacturing is big and increasing, driven by the strong underlying trend of the pharmaceutical industry to more and more introduce biotechnology as the main production method.

Today's market for bioreactors and fermentation equipment is worth billions of SEK annually. However, to lower production costs and improve productivity customers are seeking new monitoring devices that can measure glucose and other metabolite levels continuously, cost effectively and with high precision. SENZ-100G has been developed to meet these specific customer demands.

During 2009 and 2010, SENZ-100G has been tested by end-customers – large pharmaceutical companies in The Netherlands and in Sweden. Experiences from these tests have led to a number of modifications of the instrument. Senzime has been working hard towards the goal of bringing its instrument to the market during 2010 and the fact that Applikon now has decided to officially present SENZ-100G, marks its official launch. Hereby, Senzime has achieved one of its main objectives for 2010.

Senzime will continue to work closely with Applikon Biotechnology to further support the market introduction of SENZ-100G.

About Applikon Biotechnology

Applikon Biotechnology is a privately owned Dutch company developing, manufacturing and supplying on-line process analyzers and bioreactor systems for both research and production use. Founded in 1973, Applikon has grown from a small sized company to a worldwide enterprise and its business operations covers all major markets in the world, including Europe, USA, Asia and Australia.

For more information, please visit www.senzime.com or contact:

Staffan Boström, CEO
Tel. +46 (0)18 51 56 40
Mobile +46 (0)70 607 10 02
staffan.bostrom@senzime.com
www.senzime.com

About Senzime

Uppsala based Senzime, founded in 1999, has developed a biosensor which makes it possible to continuously and automatically monitor critical components in complex biological fluids. The need for such on-line measurements is increasing in a range of industries, for example in pharmaceutical production and health care.

Senzime's product offering consists of a measurement instrument and disposable sensor units, similar to the machine/filter combination one would find in a modern dialysis machine.

In parallel with working in the pharmaceutical production field (bioreactors/fermentation), Senzime has adapted its instrumented system for automated and continuous monitoring of whole blood glucose in intensive care units. The first patients were monitored by a Senzime instrument in June 2009.

The company's largest owners are members of the Crafoord family, primarily known for its key role in developing Swedish medical device company Gambro.

Senzime is a publicly listed company and its shares trade at Swedish AktieTorget (www.aktietorget.se).